Board of Directors
An accomplished board of directors provides strategic and financial guidance to enable Biostage to achieve its objectives.
Jason Jing Chen
James Shmerling, DHA, FACH
Mr. He was the Executive Vice Chairman of Bright Scholar Education Holdings Limited (NYSE listed: BEDU) until February 2023. Prior to such promotion in January 2019, Mr. He had served as the CEO of Bright Scholar since October 2015. Prior to joining Bright Scholar, Mr. He was a Managing Director at TStone Corp, and he also served as CFO, CEO and a director of Noah Education Holdings Ltd., a former NYSE listed private education services provider in China, from July 2009 to December 2011. Mr. He was a portfolio manager at Morgan Stanley Global Wealth Management from June 2008 to June 2009 and was employed by Bear Stearns from July 2006 to May 2008. Mr. He also had extensive experience working with pharmaceutical and biotech companies when he was a management consultant. Mr. He obtained a bachelor's degree in Chemistry from Peking University and a Master's degree in Chemistry, MBA with Honors from the University of Chicago. Mr. He is also a CFA charter holder.
Mr. Chen is a broadly skilled senior executive with over 20 years of leadership experience in global commerce and advancing foreign corporate interests in China. Mr. Chen joined Digitone Group in 2014 to provide leadership to optimize company visibility and interests overseas for corporate branding and positioning, and is currently CEO of Digitone’s DST Robotics business. Previously, he worked for Formica, as the General Manager of its Greater China business. He served as Vice President, Barco Great China and General Manager, Security & Monitoring Division China for Barco, Inc., a global company that develops networked solutions for the entertainment, enterprise and healthcare markets. Prior to joining Barco, Mr. Chen was the General Manger of the China and Hong Kong region for Waters Corporation where, among other managerial responsibilities, he was responsible for developing and implementing marketing strategies to grow the Chinese market. Prior to his time at Waters Corporation, Mr. Chen held various managerial rolls of increasing importance at Hilti China. Mr. Chen began his career as an electrical engineer at Capital Iron & Steel Co. He received his MBA from Brigham Young University and a BS in Electrical engineering from the North China University of Technology, Beijing, China.
David Green is the founder of Biostage. He holds a BA (honors) degree in physics from Oxford University and an MBA (with distinction) from Harvard Business School. He has worked as a brand manager for Unilever and as a strategy consultant for Monitor (now Deloitte) before co-founding Harvard Bioscience in 1996. He took HBIO public in 2000. In 2008 he founded Biostage (then called Harvard Apparatus Regenerative Technology) as a subsidiary of HBIO. He led the spinoff of Biostage from HBIO in 2013. In 2015, after a near-fatal road accident, he resigned from Biostage. He then founded Zero Carbon LLC a business that helps homeowners cut their carbon emission profitably. He is the author of three books on how cut carbon emission profitably. He has over 15 years of experience as either president or CEO of public companies. He was rehired by Biostage in November 2021. He has also been President and Director of the Harvard Business School Health Industry Alumni Association.
Dr. Shmerling is a seasoned executive who has worked in leadership roles at several pediatric hospitals around the United States during his career. For over three decades, he has served in management roles at children's hospitals across the country and is nationally recognized as a leader in issues concerning children's health and wellness. Prior to joining Connecticut Children's, he spent eight years as the Chief Executive Officer of Children's Hospital Colorado. Before that, he was the Executive Director and Chief Executive Officer of the Monroe Carell Jr. Children's Hospital at Vanderbilt from 2002 to 2007. He earned a BS in Health Education from the University of Tennessee, and MS in Hospital and Health Administration from the University of Alabama at Birmingham, an MBA from Samford University, and a Doctorate of Health Administration from the Medical University of South Carolina. Dr. Shmerling is a Fellow in the American College of Health Care Executives (ACHE). He is an adjunct faculty member in the Hospital Administration programs, University of Alabama at Birmingham.
Ms. Li brings over 20 years of investment banking experience, building relationships between customers and enterprises. Ms. Li is currently a managing partner at Donghai Securities Co., Ltd, a top asset management company in China, and also serves as the Vice President of the Jilin Enterprise Chamber of Commerce and advisor of the School of Continuing Education of Tsinghua University. Ms. Li holds a bachelor degree in accounting from China’s Changchun Taxation College in Changchun, Jilin Province, and a master’s degree in software engineering from Jilin University, also in Changchun.
Herman has been working in the life sciences industry for over 20 years in various positions including designing and running randomized trial research, optimizing of clinical administration of health services, and working as a strategic consultant to the life sciences industry. He joined Trinity over a decade ago and has worked closely with clients to support strategic decision making across the product lifecycle. Prior to joining Trinity, he worked as a Senior Associate at Boston Healthcare with device and pharmaceutical clients on product entry strategy, business development and reimbursement strategy. In his work consulting for pharmaceutical/biotech and medical device companies he has covered several diseases/therapeutic areas including oncology, rare and ultra-rare diseases, cell therapies, cardiovascular, diabetes, hepatitis C, alcohol abuse/dependence, neurological, orthopedic, and renal. He has been published in peer-reviewed publications on various topics including renal disease, suicidal ideation, minority patient recruiting, alcohol use/abuse and depression/anxiety treatment.
Ron Packard is the CEO and Founder of Pansophic Learning, a global technology based education company. Packard is a well known educator, entrepreneur and visionary as well as the author of the highly regarded and reviewed book Education Transformation. Packard was previously the long time CEO and Founder of K12 Inc. He oversaw the growth of K12 from just an idea to almost one billion in revenue, making it one of the largest education companies in the world. During his tenure, revenue compounded at near 80% and he lead the company through its IPO on the NYSE.
Before K12, Packard was the Vice President of Knowledge Universe and CEO of Knowledge Schools, one of the nation’s largest early childhood education companies. He was also instrumental in the successful investments in Learn Now, Children’s School USA, Leapfrog, TEC, and Children’s Discovery Center. Packard also worked for McKinsey & Company where he specialized in Biotechnology and Semiconductors. He previously worked for Goldman Sachs in mergers and acquisitions.
Packard has received the Education Industry Association’s James P. Boyle Entrepreneurial Leadership Award, as well as the Ernest & Young Entrepreneur of the Year Award in the IT Services & Solutions category in Greater Washington. The University of Chicago’s Booth School of Business named him a Distinguished Alumni, and he also received an Outstanding Leadership Award from the United States Distance Learning Association. He sits on the Digital Learning Council. Packard previously served on the Department of Defense’s Education Advisory Committee. He holds a B.A. from the University of California at Berkeley and an M.B.A. from the University of Chicago, both with honors. He has also earned the C.F.A designation.